Bio-Techne (NASDAQ: TECH) reported Q4 EPS of $0.87, $0.01 better than the analyst estimate of $0.86. Revenue for the quarter came in at $117.7 million versus the consensus estimate of $116.85 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.